Sutro Biopharma, Inc.
STRO
$39.69
-$1.22-2.98%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -21.35% | 13.77% | 147.98% | 33.76% | -86.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -21.35% | 13.77% | 147.98% | 33.76% | -86.98% |
| Cost of Revenue | -48.42% | -35.83% | -38.21% | -9.28% | 32.12% |
| Gross Profit | 55.55% | 43.72% | 170.00% | 22.05% | -193.78% |
| SG&A Expenses | -4.08% | -39.01% | -16.39% | 4.34% | -46.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -43.42% | -36.43% | -34.58% | -6.79% | 13.46% |
| Operating Income | 48.42% | 42.72% | 130.97% | 16.12% | -251.23% |
| Income Before Tax | 33.16% | -16.54% | 76.01% | -30.50% | -249.53% |
| Income Tax Expenses | -103.48% | -- | -325.00% | -- | -85.10% |
| Earnings from Continuing Operations | 35.45% | -16.54% | 76.05% | -30.50% | -333.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.45% | -16.54% | 76.05% | -30.50% | -333.20% |
| EBIT | 48.42% | 42.72% | 130.97% | 16.12% | -251.23% |
| EBITDA | 49.47% | 44.04% | 136.20% | 16.89% | -241.23% |
| EPS Basic | 37.42% | -12.66% | 77.00% | 3.49% | -267.94% |
| Normalized Basic EPS | 41.25% | 36.92% | 112.55% | 34.37% | -229.42% |
| EPS Diluted | 37.42% | -12.66% | 77.00% | 3.49% | -267.94% |
| Normalized Diluted EPS | 41.25% | 36.92% | 112.55% | 34.37% | -229.42% |
| Average Basic Shares Outstanding | 3.16% | 3.44% | 4.13% | 35.22% | 38.86% |
| Average Diluted Shares Outstanding | 3.16% | 3.44% | 4.13% | 35.22% | 38.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |